MITF and neoplasm: Indeed the idea of lineage-specific therapy has been subsequently proved in principle using methotrexate (MTX) to first activate MITF expression, in turn activating the tyrosinase enzyme, and thereby sensitising tumour cells to a tyrosinase-processed anti-folate prodrug (TMECG) (Sáez-Ayala et al., 2013).